Howard A. Fine, M.D., is the founding Director of the Brain Tumor Center at NewYork-Presbyterian Weill Cornell Medical Center and Associate Director for Translational Research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. He is an internationally recognized leader in the field of neuro-oncology, with more than 30 years of experience in both laboratory and clinical research as well as in the care of patients with brain tumors. Dr. Fine has built large multidisciplinary brain tumor programs at top academic institutions such as the Dana Farber Cancer Institute/Harvard Medical School and the National Institutes of Health, has cared for nearly 20,000 patients with brain and spinal cord tumors in his career, has conducted over 100 clinical trials, published over 250 papers and book chapters on brain tumors and has run a continuously operating translational genetic/molecular laboratory devoted to a better understanding of and better therapies for brain tumors for over two decades. Using pioneering technology developed in his laboratory, Dr. Fine’s translational laboratory efforts are currently focused on the construction of exact genetic miniature replicas of individual patient’s brains with their own brain tumor growing within it in a petri dish allowing for an unprecedented opportunity for studying patient-specific brain tumor biology and for real time screening for selective drugs that will be specifically effective in that individual patient. In his current capacity as Founder and Director of the Weill Cornell Brain Tumor Center, Dr. Fine spearheads a multidisciplinary approach consisting of neurosurgeons, radiation oncologists, pathologists, medical oncologists, neurologists and nutritionists at Weill Cornell Medicine for the purpose of developing a specific comprehensive treatment plan for each individual patient.